As of Dec 02
| +0.29 / +3.66%|
The 8 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 9.50, with a high estimate of 15.00 and a low estimate of 8.00. The median estimate represents a +15.71% increase from the last price of 8.21.
The current consensus among 9 polled investment analysts is to Buy stock in Array Biopharma Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.